Cross-Sector entity
Dobbs v. Jackson Women's Health Organization is most often covered alongside #WeCount report, which appears in 2 of these 2 stories. Coverage clusters in regulation, which accounts for 1 of those 2, with the remainder spread across 1 other category.
2 verified stories tracked
Last mentioned: Jun 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Dobbs v. Jackson Women's Health Organization is most often covered alongside #WeCount report, which appears in 2 of these 2 stories. Coverage clusters in regulation, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention Dobbs v. Jackson Women's Health Organization, all published on June 28, 2026. Each carries 23 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dobbs v. Jackson Women's Health Organization. Shared-story counts are live from our verified record — not editorial picks.
Federal Appeals Court Bans Mailing Mifepristone
A federal appeals court made it illegal to mail mifepristone, a key medication abortion pill, threatening telehealth access.
Supreme Court Issues Stay on Mifepristone Ban
The Supreme Court stayed the appeals court ruling, allowing mailing to continue while the legal challenge proceeds.
Supreme Court Overturns Roe v. Wade in Dobbs Decision
The landmark ruling eliminated the constitutional right to abortion, allowing states to enact bans.
Despite state bans, U.S. abortions nearly doubled, fueled by telehealth pill delivery across state lines. This exposes legal tensions between state authority, FDA preemption, and 19th-century obscenity statutes.
U.S. abortions nearly doubled between 2021 and 2025, with medication abortion now 63% of the total. Telehealth delivery has enabled this surge, though misoprostol-only use raises clinical concerns.
Source: wyomingpublicmedia.org · news.wjct.org
